1.Small nucleolar RNA host gene 1 (SNHG1) facilitates gemcitabine chemosensitivity in gallbladder cancer by regulating the miR-23b-3p/phosphatase and tensin homolog (PTEN) pathway.
Hui WANG ; Yixiang GU ; Miaomiao GUO ; Ming ZHAN ; Min HE ; Yang ZHANG ; Linhua YANG ; Yingbin LIU
Chinese Medical Journal 2025;138(21):2783-2792
BACKGROUND:
Growing evidence suggests that long non-coding RNAs (lncRNAs) exert pivotal roles in fostering chemoresistance across diverse tumors. Nevertheless, the precise involvement of lncRNAs in modulating chemoresistance within the context of gallbladder cancer (GBC) remains obscure. This study aimed to uncover how lncRNAs regulate chemoresistance in gallbladder cancer, offering potential targets to overcome drug resistance.
METHODS:
To elucidate the relationship between gemcitabine sensitivity and small nucleolar RNA host gene 1 ( SNHG1 ) expression, we utilized publicly available GBC databases, GBC tissues from Renji Hospital collected between January 2017 and December 2019, as well as GBC cell lines. The assessment of SNHG1, miR-23b-3p, and phosphatase and tensin homolog (PTEN) expression was performed using in situ hybridization, quantitative real-time polymerase chain reaction, and western blotting. The cell counting kit-8 (CCK-8) assay was used to quantify the cell viability. Furthermore, a GBC xenograft model was employed to evaluate the impact of SNHG1 on the therapeutic efficacy of gemcitabine. Receiver operating characteristic (ROC) curve analyses were executed to assess the specificity and sensitivity of SNHG1.
RESULTS:
Our analyses revealed an inverse correlation between the lncRNA SNHG1 and gemcitabine resistance across genomics of drug sensitivity in cancer (GDSC) and Gene Expression Omnibus (GEO) datasets, GBC cell lines, and patients. Gain-of-function investigations underscored that SNHG1 heightened the gemcitabine sensitivity of GBC cells in both in vitro and in vivo settings. Mechanistic explorations illuminated that SNHG1 could activate PTEN -a commonly suppressed tumor suppressor gene in cancers-thereby curbing the development of gemcitabine resistance in GBC cells. Notably, microRNA (miRNA) target prediction algorithms unveiled the presence of miR-23b-3p binding sites within SNHG1 and the 3'-untranslated region (UTR) of PTEN . Moreover, SNHG1 acted as a sponge for miR-23b-3p, competitively binding to the 3'-UTR of PTEN , thereby amplifying PTEN expression and heightening the susceptibility of GBC cells to gemcitabine.
CONCLUSION
The SNHG1/miR-23b-3p/PTEN axis emerges as a pivotal regulator of gemcitabine sensitivity in GBC cells, holding potential as a promising therapeutic target for managing GBC patients.
Humans
;
Deoxycytidine/pharmacology*
;
PTEN Phosphohydrolase/genetics*
;
Gemcitabine
;
RNA, Long Noncoding/metabolism*
;
MicroRNAs/genetics*
;
Gallbladder Neoplasms/genetics*
;
Cell Line, Tumor
;
Animals
;
Mice
;
Drug Resistance, Neoplasm/genetics*
;
Mice, Nude
;
Antimetabolites, Antineoplastic
;
Gene Expression Regulation, Neoplastic
2.Two new sesquiterpenoids from Aucklandiae Radix and their farnesoid X receptor agonist activity.
Qian-Yu CHEN ; Dan HUANG ; Hong-Hong ZHAN ; Fan-Cheng MENG ; Guo-Wei WANG ; Min CHEN
China Journal of Chinese Materia Medica 2025;50(7):1810-1816
Various chromatographic methods were comprehensively applied to study the chemical composition of the ethyl acetate extract from Aucklandiae Radix. The structures of all compounds were identified by analyzing their physicochemical properties and using spectroscopic methods. Two new sesquiterpenoids, named auclappsines A and B(1 and 2) were isolated and identified. Through in vitro high content screening and with the use of a guggulsterone-induced L02 cells, the effects of 1 and 2 on farnesoid X receptor(FXR) protein expression were investigated. The results showed that 1 had a significant FXR activation effect, providing a scientific basis for the development of drugs for the treatment of liver and gallbladder diseases.
Receptors, Cytoplasmic and Nuclear/genetics*
;
Humans
;
Sesquiterpenes/isolation & purification*
;
Drugs, Chinese Herbal/isolation & purification*
;
Cell Line
;
Molecular Structure
3.Clinical trial of Morinda officinalis oligosaccharides in the continuation treatment of adults with mild and moderate depression
Shu-Zhe ZHOU ; Zu-Cheng HAN ; Xiu-Zhen WANG ; Yan-Qing CHEN ; Ya-Ling HU ; Xue-Qin YU ; Bin-Hong WANG ; Guo-Zhen FAN ; Hong SANG ; Ying HAI ; Zhi-Jie JIA ; Zhan-Min WANG ; Yan WEI ; Jian-Guo ZHU ; Xue-Qin SONG ; Zhi-Dong LIU ; Li KUANG ; Hong-Ming WANG ; Feng TIAN ; Yu-Xin LI ; Ling ZHANG ; Hai LIN ; Bin WU ; Chao-Ying WANG ; Chang LIU ; Jia-Fan SUN ; Shao-Xiao YAN ; Jun LIU ; Shou-Fu XIE ; Mao-Sheng FANG ; Wei-Feng MI ; Hong-Yan ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(6):815-819
Objective To observe the efficacy and safety of Morinda officinalis oligosaccharides in the continuation treatment of mild and moderate depression.Methods An open,single-arm,multi-center design was adopted in our study.Adult patients with mild and moderate depression who had received acute treatment of Morinda officinalis oligosaccharides were enrolled and continue to receive Morinda officinalis oligosaccharides capsules for 24 weeks,the dose remained unchanged during continuation treatment.The remission rate,recurrence rate,recurrence time,and the change from baseline to endpoint of Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA),Clinical Global Impression-Severity(CGI-S)and Arizona Sexual Experience Scale(ASEX)were evaluated.The incidence of treatment-related adverse events was reported.Results The scores of HAMD-17 at baseline and after treatment were 6.60±1.87 and 5.85±4.18,scores of HAMA were 6.36±3.02 and 4.93±3.09,scores of CGI-S were 1.49±0.56 and 1.29±0.81,scores of ASEX were 15.92±4.72 and 15.57±5.26,with significant difference(P<0.05).After continuation treatment,the remission rate was 54.59%(202 cases/370 cases),and the recurrence rate was 6.49%(24 cases/370 cases),the recurrence time was(64.67±42.47)days.The incidence of treatment-related adverse events was 15.35%(64 cases/417 cases).Conclusion Morinda officinalis oligosaccharides capsules can be effectively used for the continuation treatment of mild and moderate depression,and are well tolerated and safe.
4.Research status of programmed cell death in pathogenesis of acute pancreatitis
Yu ZHANG ; Min BAI ; Zhan-dong WANG ; Yuan LIAN ; Qiong WANG ; Bing SONG ; Chao GUO ; Yong-feng WANG ; Yan-ying ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(23):3492-3496
Acute pancreatitis(AP)is one of the most common clinically critical diseases,and pancreatic acinar cell death is a central event in the pathological course of AP and a key factor in determining the degree of local or systemic inflammatory damage as well as overall pancreatitis.Programmed cell death is an active and orderly way of death that is regulated by program and widely exists in the development of organisms.A variety of programmed death modes are widely involved in the damage of AP acinar cells,mainly including autophagy,pyrodeath and iron death,etc.This study systematically reviews the mechanism of programmed death in AP acinar cells.The aim is to provide a new understanding of the specific pathogenesis of AP,and to provide new ideas and strategies for the treatment of the disease.
5.Research status of traditional Chinese medicine regulating endoplasmic reticulum stress in the treatment of osteoporosis
Ting-ting CAO ; Min BAI ; Zhan-dong WANG ; Feng-zhe YAN ; Wen-jing SONG ; Chao GUO ; Yong-feng WANG ; Bing SONG ; Yan-ying ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(24):3643-3647
Osteoporosis(OP)is a bone-related disease characterized by an imbalance between bone resorption and bone formation.Recent studies have shown that endoplasmic reticulum stress(ERS)plays an important role in the pathogenesis of OP.On the one hand,moderate ERS can regulate the differentiation of mesenchymal stem cells,osteoblasts and osteoclasts through multiple signaling pathways to promote bone homeostasis.On the other hand,excessive ERS can induce apoptosis of bone-related cells through various ways to disrupt bone homeostasis.Traditional Chinese medicine monomer and compound have significant therapeutic effect on OP.Recent studies have found that regulating ERS is one of the important mechanisms of effective treatment of OP by traditional Chinese medicine.From the perspective of ER stress,many studies have explored the mechanism of action in the treatment of OP by Chinese medicine.In this paper,through analyzing and summarizing the literature at home and abroad in recent years,the relevant studies on the involvement of ERS process in osteoporosis and the studies on the treatment of OP by Chinese medicine ERS process were reviewed.To further reveal the involvement of ERS process in the pathogenesis of osteoporosis and the regulatory role of traditional Chinese medicine.
6.Research status of programmed cell death in pathogenesis of acute pancreatitis
Yu ZHANG ; Min BAI ; Zhan-dong WANG ; Yuan LIAN ; Qiong WANG ; Bing SONG ; Chao GUO ; Yong-feng WANG ; Yan-ying ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(23):3492-3496
Acute pancreatitis(AP)is one of the most common clinically critical diseases,and pancreatic acinar cell death is a central event in the pathological course of AP and a key factor in determining the degree of local or systemic inflammatory damage as well as overall pancreatitis.Programmed cell death is an active and orderly way of death that is regulated by program and widely exists in the development of organisms.A variety of programmed death modes are widely involved in the damage of AP acinar cells,mainly including autophagy,pyrodeath and iron death,etc.This study systematically reviews the mechanism of programmed death in AP acinar cells.The aim is to provide a new understanding of the specific pathogenesis of AP,and to provide new ideas and strategies for the treatment of the disease.
7.Research status of traditional Chinese medicine regulating endoplasmic reticulum stress in the treatment of osteoporosis
Ting-ting CAO ; Min BAI ; Zhan-dong WANG ; Feng-zhe YAN ; Wen-jing SONG ; Chao GUO ; Yong-feng WANG ; Bing SONG ; Yan-ying ZHANG
The Chinese Journal of Clinical Pharmacology 2024;40(24):3643-3647
Osteoporosis(OP)is a bone-related disease characterized by an imbalance between bone resorption and bone formation.Recent studies have shown that endoplasmic reticulum stress(ERS)plays an important role in the pathogenesis of OP.On the one hand,moderate ERS can regulate the differentiation of mesenchymal stem cells,osteoblasts and osteoclasts through multiple signaling pathways to promote bone homeostasis.On the other hand,excessive ERS can induce apoptosis of bone-related cells through various ways to disrupt bone homeostasis.Traditional Chinese medicine monomer and compound have significant therapeutic effect on OP.Recent studies have found that regulating ERS is one of the important mechanisms of effective treatment of OP by traditional Chinese medicine.From the perspective of ER stress,many studies have explored the mechanism of action in the treatment of OP by Chinese medicine.In this paper,through analyzing and summarizing the literature at home and abroad in recent years,the relevant studies on the involvement of ERS process in osteoporosis and the studies on the treatment of OP by Chinese medicine ERS process were reviewed.To further reveal the involvement of ERS process in the pathogenesis of osteoporosis and the regulatory role of traditional Chinese medicine.
8.Genome sequence analysis of two SARS-CoV-2 virus infections in Inner Mongolia, 2022.
Guo Qing YANG ; Chao MIN ; Jian SONG ; Xiao Feng JIANG ; Hua YUE ; Xiao Wei NAN ; Zhen YAN ; Ai Tao LU ; Yan HAI ; Zhan Song ZHU
Chinese Journal of Preventive Medicine 2023;57(10):1630-1634
The target gene sequences of the novel coronaviruses obtained by sequencing were compared with the reference sequences to analyze the genetic variation of the two cases of the novel coronaviruses from Inner Mongolia Autonomous Region in 2022 and to explore the sources of infection. The results showed that the two sequences belonged to different evolutionary branches, Delta (AY.122) and Omicron (BA.1.1), respectively. hCoV-19/Inner Mongolia/IVDC-591/2022 had 48 single nucleotide polymorphisms on the genome sequences, sharing 40 nucleotide mutation sites with a Mongolian strain; hCoV-19/Inner Mongolia/IVDC-592/2022 genome shared 57 nucleotide mutation sites with a UK strain, and the nucleotide mutation site identity was 100% (57/57). Phylogenetic analysis showed that the target gene sequences were not directly related to domestic novel coronavirus sequences during the same period, but were related to isolates from Europe and Mongolia.
Humans
;
COVID-19
;
SARS-CoV-2/genetics*
;
Phylogeny
;
Genome, Viral
;
Nucleotides
;
Sequence Analysis
9.Genome sequence analysis of two SARS-CoV-2 virus infections in Inner Mongolia, 2022.
Guo Qing YANG ; Chao MIN ; Jian SONG ; Xiao Feng JIANG ; Hua YUE ; Xiao Wei NAN ; Zhen YAN ; Ai Tao LU ; Yan HAI ; Zhan Song ZHU
Chinese Journal of Preventive Medicine 2023;57(10):1630-1634
The target gene sequences of the novel coronaviruses obtained by sequencing were compared with the reference sequences to analyze the genetic variation of the two cases of the novel coronaviruses from Inner Mongolia Autonomous Region in 2022 and to explore the sources of infection. The results showed that the two sequences belonged to different evolutionary branches, Delta (AY.122) and Omicron (BA.1.1), respectively. hCoV-19/Inner Mongolia/IVDC-591/2022 had 48 single nucleotide polymorphisms on the genome sequences, sharing 40 nucleotide mutation sites with a Mongolian strain; hCoV-19/Inner Mongolia/IVDC-592/2022 genome shared 57 nucleotide mutation sites with a UK strain, and the nucleotide mutation site identity was 100% (57/57). Phylogenetic analysis showed that the target gene sequences were not directly related to domestic novel coronavirus sequences during the same period, but were related to isolates from Europe and Mongolia.
Humans
;
COVID-19
;
SARS-CoV-2/genetics*
;
Phylogeny
;
Genome, Viral
;
Nucleotides
;
Sequence Analysis
10.Efficacy and Safety of Bushen Huoxue Formula in Patients with Discogenic Low-Back Pain: A Double-Blind, Randomized, Placebo-Controlled Trial.
Jia-Wen ZHAN ; Kai-Ming LI ; Li-Guo ZHU ; Shang-Quan WANG ; Min-Shan FENG ; Xu WEI ; Jie YU ; Bin TANG ; Xun-Lu YIN ; Tao HAN ; Ping ZHANG ; Ling-Hui LI ; Ming CHEN ; Chen-Chen SHAO
Chinese journal of integrative medicine 2022;28(11):963-970
OBJECTIVE:
To assess the efficacy and safety of Bushen Huoxue Formula (BSHXF) for the treatment of discogenic low-back pain (DLBP).
METHODS:
This was a parallel, double-blind, randomized, clinical trial performed between May 2019 and June 2020. Seventy patients were assigned by computerized random number table to the treatment group (lumbar traction and BSHXF, 35 cases) or the control group (lumbar traction and placebo, 35 cases). The patients received intervention for 3 weeks. Assessment was conducted before treatment and at week 1, 2, 3 during treatment. Primary outcome was the self-reported score of Oswestry Disability Index (ODI). Secondary outcomes included Visual Analog Scale (VAS), clinical efficacy rate by minimal clinically important difference (MCID) as well as lumbar tenderness, muscle tone and lumbar spine mobility. Adverse reactions were recorded. Follow-up was performed at 1 and 3 months after the end of treatment.
RESULTS:
In the treatment group, ODI score was significantly decreased compared with baseline (P<0.05) and the control group at 2- and 3- week treatment. Similarly, VAS score decreased compared with the baseline (P<0.05) and was lower than that in the control group at 2- and 3- week treatment (P<0.05). The clinical efficacy rate of the treatment group was higher than that of the control group after treatment [32.35% (11/34) vs. 3.13% (1/32), P<0.05). Moreover, the tenderness, and muscle tone, as well as the back extension and left flexion in lumbar spine mobility in the treatment group at 3-week treatment were significantly improved compared with the control group (P<0.05). Follow-up showed that at 1-month after treatment, the treatment group had better outcomes than the control group with regard to a total score of ODI and VAS scores, as well as clinical efficacy rate (all P<0.05). Moreover, VAS score was still significantly lower than the control group at 3-month follow-up (P<0.05). No adverse reactions were reported during the study.
CONCLUSION
BSXHF combined with lumbar traction can significantly improve the clinical symptoms including pain intensity, functionality, muscle tone, and lumbar spine mobility in DLBP patients. (Registration No. ChiCTR1900027777).
Humans
;
Intervertebral Disc Degeneration/therapy*
;
Low Back Pain/drug therapy*
;
Lumbar Vertebrae
;
Pain Measurement
;
Treatment Outcome

Result Analysis
Print
Save
E-mail